From: Targeting immune checkpoints in hematological malignancies
Clinical trial | Phase | Patient characteristics | Intervention | Response | Reference |
---|---|---|---|---|---|
NCT01592370 | I | Relapsed or refractory HL | Nivolumab | ORR 87% | [46] |
CheckMate 205 (NCT02181738) | II | cHLCohort A: brentuximab vedotin naïve Cohort B: brentuximab vedotin after auto-HCT Cohort C: brentuximab vedotin before and/or after auto-HCT Cohort D: nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine for newly diagnosed HL | Nivolumab | ORR: Cohort A 65% Cohort B 68% Cohort C 73% Cohort D 84% | |
KEYNOTE-013 (NCT01953692) | I | cHL after brentuximab vedotin failure | Pembrolizumab | ORR 65% | [49] |
KEYNOTE-087 (NCT02453594) | II | Relapsed or refractory cHL, Cohort 1: after ASCT/brentuximab vedotin Cohort 2: ineligible for ASCT and experienced treatment failure with brentuximab vedotin Cohort 3: No brentuximab vedotin after ASCT | Pembrolizumab | ORR: Cohort 1 73.9% Cohort 2 64.2% Cohort 3 70% | [50] |
NCT02038933 | II | Relapsed or refractory DLBCL Cohort 1: auto-HCT-failed Cohort 2: auto-HCT-ineligible | Nivolumab | ORR: Cohort 1 10% Cohort 2 3% | [51] |
NCT02446457 | II | Relapsed FL | Pembrolizumab Rituximab | Pre-planned interim analysis: ORR 80% | [52] |
NCT03245021 | II | Previously untreated FL | Single-agent nivolumab followed by combined nivolumab and rituximab | Pre-planned interim analysis: ORR 84% | [53] |
NCT03278782 | I/II | Relapsed or refractory peripheral T cell lymphoma (PTCL) | Pembrolizumab Romidepsin | ORR 44% | [54] |
NCT02243579 | II | Recurrent mycosis fungoides and Sezary syndrome | Pembrolizumab | ORR 38% | [55] |
KEYNOTE-023 (NCT02036502) | I | Relapsed or refractory MM | Pembrolizumab combined with lenalidomide and low-dose dexamethasone | ORR 44% | [56] |
KEYNOTE-183 (NCT02576977) | III | Relapsed or refractory MM | Pembrolizumab plus pomalidomide and dexamethasone | Pembrolizumab plus pomalidomide and dexamethasone group: Median PFS: 5.6 months (95% CI 3.7–7.5); Pomalidomide and dexamethasone group: 8.4 months (5.9–not reached) | [57] |
KEYNOTE-185 (NCT02579863) | III | Treatment-naive MM | Pembrolizumab plus lenalidomide and dexamethasone | Progression-free survival estimates at 6-months were 82.0% (95% CI 73.2–88.1) versus 85.0% (76.8–90.5; hazard ratio [HR] 1.22; 95% CI 0.67–2.22; p = 0.75) | [58] |
NCT01822509 | I | Patients with relapse after allogeneic transplantation: AML (in 12 patients, including 3 with leukemia cutis and 1 with a myeloid sarcoma), HL (in 7), NHL (in 4), and myelodysplastic syndrome (in 2). One patient each had MM, myeloproliferative neoplasm, and acute lymphoblastic leukemia | Ipilimumab | Patients that received a dose of 10 mg/kg: CR (23%) | [59] |
NCT02397720 | II | Relapsed or refractory AML | Azacitidine and nivolumab | ORR 33% | [60] |